Not FDA approved and sold as a research chemical. This page is educational information only. It is not medical advice and not a recommendation to use anything.

IndexedBuilt automatically from public databases on 2026-09-30. Not yet hand-reviewed by PLOBT.How this works →

CJC-1295 no DAC

Not FDA approved

GHRH analog peptide

Also known as: Mod GRF 1-29, modified GRF 1-29

Evidence score

9/ 100

Thin evidence

Very thin human evidence

Regulatory standing. Sold as a research chemical, not approved
Anecdotal. Community reports, no controlled data
No registered human trials. Nothing registered on ClinicalTrials.gov
No sources. Nothing cited to verify

Computed with the same four public criteria as every profile. The human-evidence grade on an indexed profile is set automatically and may change when it is hand-reviewed. It is not a safety score, not a purity rating, and not medical advice, and not a claim that this compound treats, cures, or prevents any condition.

What it is

CJC-1295 no DAC, also called Mod GRF 1-29, is a synthetic, modified version of the first 29 amino acids of growth hormone releasing hormone (GHRH). It is thought to act on GHRH receptors in the pituitary to prompt release of growth hormone, with amino acid substitutions intended to make it more stable than the natural fragment. Unlike the DAC version, it lacks the drug affinity complex that extends its time in the body.

What the evidence shows

Automatic summaryAnecdotal

This compound is not FDA-approved, has no registered human trials, and has only about one published paper, so its effects and safety in humans are essentially unestablished. Most claims about it come from community reports and from research on related GHRH analogs rather than direct study of this specific peptide.

Registered human trials

Live from ClinicalTrials.gov, refreshed daily.

0registered studies

Nonemost advanced phase

0completed (sample)

0recruiting (sample)

Published literature

Live from Europe PMC. This is how much has been published, not how much is proven in humans.

1papers referencing CJC-1295 no DAC

The emerging landscape of performance-enhancing peptides modulating GH-IGF1 axis: bridging the gap between clinical evidence and patient self-administration.

Front Endocrinol (Lausanne)2026

Sources

Risks, side effects and study doses are only published on hand-reviewed profiles. Want this one reviewed, or spotted something wrong? Tell us.